Business Context and Reporting Period
The filing is a Form 20-F for the fiscal year ended December 31, 2020. The registrant identified in the filing is MeaTech 3D Ltd., an Israeli development-stage food-technology company; the requested company name, Steakholder Foods Ltd., does not appear in the supplied filing text.
The company is developing three-dimensional bioprinting, bio-ink, cell-culture and tissue-growth technologies intended to enable customers to manufacture cultured meat without animal slaughter. It had no commercial products or operating revenue from its cultured-meat activities during 2020.
Key Financial Metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.491 million | $0.166 million |
| Marketing expense | $0.506 million | $0 |
| General and administrative expense | $5.380 million | $0.256 million |
| Public listing expense | $10.164 million | $0 |
| Operating loss | $18.541 million | $0.422 million |
| Net loss | $18.524 million | $0.423 million |
| Basic and diluted loss per share | $0.308 | $0.022 |
| Cash used in operating activities | $3.832 million | $0.173 million |
| Cash used in investing activities | $1.875 million | $0.253 million |
| Cash provided by financing activities | $17.345 million | $1.648 million |
| Cash and cash equivalents at year-end | $13.556 million | $1.274 million |
| Total assets | $17.474 million | $1.987 million |
| Total liabilities | $1.843 million | $0.496 million |
| Total capital | $15.631 million | $1.491 million |
All amounts are in U.S. dollars unless otherwise stated and are presented under IFRS. Gross and operating margins are not meaningful because revenue was zero. The company reported no traditional debt securities; liabilities primarily comprised payables, lease liabilities and a derivative related to price-protection mechanisms.
Material Changes Versus the Prior Comparable Period
- Research and development spending increased approximately 1,150% to $2.491 million as the company expanded cultured-meat development.
- General and administrative expense increased approximately 1,700% to $5.380 million, primarily due to personnel, share-based compensation and professional services.
- Marketing expense began in 2020 and totaled $0.506 million.
- Net loss increased by approximately $18.1 million. The increase was driven substantially by the $10.164 million non-cash public listing expense associated with the January 2020 reverse acquisition, as well as higher operating expenses.
- Operating cash burn increased to $3.832 million from $0.173 million, while financing inflows rose to $17.345 million through equity and warrant issuances and option exercises.
- Cash increased by $12.282 million year over year to $13.556 million, supported principally by financing activities rather than operations.
- The company completed an initial investment in Peace of Meat BV in 2020 and completed the acquisition of the remaining shares in February 2021 for consideration of up to approximately $17.2 million, including cash, ordinary shares and milestone-based consideration.
Guidance, Outlook, Risks and Unusual Items
- Management stated that existing cash and cash equivalents were expected to fund projected needs until December 2022, but acknowledged that additional equity, debt or strategic financing may be required and may not be available on acceptable terms.
- The company did not expect near-term operating revenue. Commercial revenue depends on completing development, obtaining any required regulatory acceptance, securing licensees or collaborators and achieving market acceptance.
- Management targeted printing 100 grams of structured, edible cultured meat tissue by the end of 2021, followed by efforts to scale the process to industrial levels. This is a forward-looking development target, not reported commercial output.
- The business had a limited operating history, no approved products, no established sales or manufacturing infrastructure and an unproven business model. Management expected continued significant losses and negative operating cash flow.
- COVID-19 caused a temporary facility closure and delayed some development activities. The filing states that the ultimate impact remained uncertain.
- Regulatory frameworks for cultured meat were emerging. Potential restrictions on food safety, product approval, labeling and the use of terms such as “meat” or “beef” could delay or prevent commercialization.
- The company relied on equity financing and had substantial dilution exposure from outstanding options, warrants, restricted stock units and milestone-based founder rights. Approximately 45.8 million potentially dilutive instruments were excluded from diluted loss-per-share calculations at December 31, 2020 because they were anti-dilutive.
- In November 2020, the Israel Securities Authority initiated an administrative proceeding concerning reports issued by predecessor Ophectra in 2017 and 2018. In April 2021, the company agreed to a $0.21 million settlement, subject to approval by the ISA Enforcement Committee.
- A February 2021 civil claim relating to predecessor Ophectra sought approximately $0.8 million from the settlement fund. Management assessed the probability of a final judgment against the fund as low and stated that the company’s exposure was limited beyond the value of the retained Therapin asset.
- Subsequent to year-end, the company completed a Nasdaq IPO in March 2021, raising approximately $24.7 million in net proceeds. The ADSs began trading under the symbol MITC.
Most Important Facts for Investors to Verify
- Confirm the issuer’s current legal name and corporate history, because the supplied filing identifies MeaTech 3D Ltd., not Steakholder Foods Ltd.
- Review the audited IFRS financial statements and reconcile the $10.164 million non-cash public listing expense to the January 2020 reverse acquisition.
- Assess cash runway against ongoing operating losses, planned research spending, the Peace of Meat acquisition obligations and the stated December 2022 funding horizon.
- Verify the status and potential dilution from options, warrants, restricted stock units and founder milestone rights.
- Track progress toward commercial-scale production, including the 100-gram cultured-tissue target and subsequent industrial-scale milestones.
- Evaluate regulatory approvals, labeling requirements and market acceptance risks for cultured-meat products and related technologies.
- Confirm the final resolution of the ISA proceeding and any claims involving the predecessor’s settlement fund.
- Review the March 2021 Nasdaq offering, subsequent share count changes and the terms of the Peace of Meat acquisition.